https://go.evvnt.com/962505-0?pid=5248 Omni Parker House
60 School Street
Boston, Massachusetts 02108
Lectures & Conferences
Built with Genentech, AstraZeneca, Starpharma, Avidity, and Guardian Therapeutics, join 80+ key leaders and decision makers as they reimagine traditional ADCs and discuss their novel format technologies.
The inaugural Novel Format Conjugates Summit exclusively focuses on the common challenges across early research and development of next generation Non-Traditional 'ADCs', or alternative format conjugates approaches for oncology and beyond. This meeting delves into the different technologies of these novel-format conjugates, exploring how conjugation chemistry is affected for different kinds of therapeutic modalities, and the impact an alternative format ADC has on targeting.
As we look to the future of drug development of novel conjugates, you will get the chance to hear the cutting-edge science accelerating the development of Bispecific ADCs, Radio-conjugates, ISACs, SMDCs, Probody conjugates, Liposomal drug conjugates, Oligonucleotide conjugates and many more.
Engage in cross-industry discussions and presentations from over 20 expert speakers across 3 unmissable days and equip yourself with the tools to develop novel format ADCs with an improved therapeutic potential so we can bring more drugs to patients of unmet needs.
Industry Pricing - Conference + 2 Workshops: USD 4297.0,
Industry Pricing - Conference + 1 Workshop: USD 3648.0,
Industry Pricing - Conference Only: USD 2999.0,
Solution Provider Pricing - Conference + 2 Workshops: USD 5097.0,
Solution Provider Pricing - Conference + 1 Workshop: USD 4348.0,
Solution Provider Pricing - Conference Only: USD 3599.0,
Academic Pricing - Conference + 2 Workshops: USD 3697.0,
Academic Pricing - Conference + 1 Workshop: USD 3148.0,
Academic Pricing - Conference Only: USD 2599.0
Speakers: Alain Wagner Director BioFunctional Chemistry Lab, Amy Han Senior Director Regeneron, Andrea Galbiati Research Scientist Philogen, Cari Meisel Director of Research and Development NanoTomer, Christian Marsolais Chief Medical Officer and Vice President of Medical Affairs Theratechnologies, Christina McGuire Senior Scientist Guardian Therapeutics, David Owen Vice President Research and Development Starpharma, Edward Barnes Technical Director Aptamer Group, Fu-An Kang Vice President Research miRecule, Gavin Bennet Head of Pre-Clinical Development Bicycle Therapeutics, Gordon Rigg Principal Consultant Apex Biologics Consulting, Hans Georg Lerchen Chief Scientific Officer Vincerx Pharma, Jarrod Longcor Chief Business Officer and SVP of Operations Cellectar Biosciences, John Flygare Senior Principal Scientist Merck, Mahendra Deonorain Chief Executive Officer, Chief Science and Operating Officer Antikor Biopharma, Mark Frigerio Vice President - Design and Developability Abzena, Michael Alonso Vice President of Immunology and Pharmacology Bolt Biotherapeutics, Mike Wheatcroft Chief Scientist Telix Pharmaceuticals, Mingchao Kang Project Leader, EuCode Ambrx, Nick Yoder Direction, Bioconjugation Magenta Therapeutics, Ramana Doppalapudi Vice President of Chemistry Avidity Biosciences, Ruben Postel Founder and Chief Scientific Officer Sapreme Technologies, Shelley Ackerman Associate Director and Project Team Lead Bolt Biotherapeutics, Thomas Pillow Senior Scientist Genentech, Timothy Weeden Senior Director and Head of Platform Development Dyne Therapeutics, Yi-Shen Zhu Professor Nanjing Tech University, Zhibo Lui Principal Investigator Peking University